DK1624871T3 - Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger - Google Patents

Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger

Info

Publication number: DK1624871T3
Authority: DK; Denmark
Prior art keywords: dyslipidemia; pharmaceutical compositions; related conditions; treating atherosclerosis; atherosclerosis
Prior art date: 2003-05-15

Application number

DK04785539T

Other languages

English (en)

Inventor

Kang Cheng

M Gerard Waters

Kathleen M Metters

Gary O'neill

Original Assignee

Merck & Co Inc

Merck Frosst Canada Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-15

Filing date

2004-05-13

Publication date

2009-11-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1624871(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-13 Application filed by Merck & Co Inc, Merck Frosst Canada Ltd filed Critical Merck & Co Inc

2009-11-16 Application granted granted Critical

2009-11-16 Publication of DK1624871T3 publication Critical patent/DK1624871T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK04785539T 2003-05-15 2004-05-13 Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger DK1624871T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47066503P	2003-05-15	2003-05-15
PCT/US2004/014980 WO2004103370A1 (en)	2003-05-15	2004-05-13	Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
DK1624871T3 true DK1624871T3 (da)	2009-11-16

Family

ID=33476734

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04785539T DK1624871T3 (da)	2003-05-15	2004-05-13	Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger
DK09163448.5T DK2116244T3 (da)	2003-05-15	2004-05-13	Method of treating atherosclerosis, dyslipidemias and related conditions

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK09163448.5T DK2116244T3 (da)	2003-05-15	2004-05-13	Method of treating atherosclerosis, dyslipidemias and related conditions

Country Status (44)

Country	Link
US (4)	US20040229844A1 (da)
EP (3)	EP1624871B1 (da)
JP (2)	JP4637833B2 (da)
KR (2)	KR100960749B1 (da)
CN (3)	CN101559227B (da)
AR (1)	AR041089A1 (da)
AU (2)	AU2004240597B2 (da)
BR (1)	BRPI0410273A (da)
CA (1)	CA2525772C (da)
CL (1)	CL2004001056A1 (da)
CO (1)	CO5630034A2 (da)
CR (2)	CR8047A (da)
CY (2)	CY1109476T1 (da)
DE (1)	DE602004022036D1 (da)
DK (2)	DK1624871T3 (da)
DO (1)	DOP2004000907A (da)
EA (2)	EA011895B1 (da)
EC (1)	ECSP056156A (da)
ES (2)	ES2328148T3 (da)
GE (2)	GEP20105025B (da)
GT (1)	GT200400098A (da)
HN (1)	HN2004000171A (da)
HR (2)	HRP20090424T1 (da)
IL (1)	IL171962A (da)
IS (1)	IS2708B (da)
JO (1)	JO2564B1 (da)
MA (1)	MA27835A1 (da)
ME (1)	MEP60108A (da)
MX (1)	MXPA05012272A (da)
MY (1)	MY140639A (da)
NO (1)	NO20055957L (da)
NZ (2)	NZ572515A (da)
PA (1)	PA8603201A1 (da)
PE (1)	PE20050552A1 (da)
PL (2)	PL1624871T3 (da)
PT (2)	PT2116244E (da)
RS (3)	RS20120499A1 (da)
SG (1)	SG153667A1 (da)
SI (2)	SI1624871T1 (da)
TN (1)	TNSN05290A1 (da)
TW (2)	TWI341199B (da)
UA (1)	UA89615C2 (da)
WO (1)	WO2004103370A1 (da)
ZA (1)	ZA200508288B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002302248B2 (en) *	2001-05-23	2008-03-06	Merck Frosst Canada Ltd.	Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
WO2004083388A2 (en) *	2003-03-14	2004-09-30	Bristol-Myers Squibb Company	Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es)	2003-10-31	2005-08-25	Arena Pharm Inc	Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
DE14172396T1 (de)	2004-10-08	2015-01-08	Forward Pharma A/S	Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006078776A2 (en) *	2005-01-19	2006-07-27	The Trustees Of The University Of Pennsylvania	Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
US20080139604A1 (en) *	2005-02-17	2008-06-12	Shaun Fitzpatrick	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
JP2008538277A (ja) *	2005-02-18	2008-10-23	アリーナファーマシューティカルズ，インコーポレイテッド	脂質関連障害の治療用の組成物および方法
US7750015B2 (en) *	2005-05-17	2010-07-06	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1885726B1 (en) *	2005-05-17	2016-12-14	Merck Sharp & Dohme Corp.	Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2007027532A2 (en) *	2005-08-29	2007-03-08	Merck & Co., Inc.	Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007027855A2 (en) *	2005-09-01	2007-03-08	Array Biopharma Inc.	Raf inhibitor compounds and methods of use thereof
WO2007042035A2 (en) *	2005-10-07	2007-04-19	Aditech Pharma Ab	Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
CN101378807A (zh) *	2005-12-21	2009-03-04	先灵公司	H3拮抗剂/反相激动剂与食欲抑制剂的组合
WO2007075702A2 (en) *	2005-12-21	2007-07-05	Schering Corporation	Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
AU2007208478A1 (en) *	2006-01-20	2007-08-02	Schering Corpooration	Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
US20090069275A1 (en) *	2006-02-17	2009-03-12	Rocca Jose G	Low flush niacin formulation
WO2008033465A1 (en) *	2006-09-15	2008-03-20	Schering Corporation	Azetidinone derivatives and methods of use thereof
US20080070890A1 (en) *	2006-09-15	2008-03-20	Burnett Duane A	Spirocyclic Azetidinone Compounds and Methods of Use Thereof
JP2010503677A (ja) *	2006-09-15	2010-02-04	シェーリングコーポレイション	脂質代謝の障害を治療するためのアゼチジノン誘導体
WO2008039882A1 (en) *	2006-09-30	2008-04-03	Sanofi-Aventis U.S. Llc	A combination of niacin and a prostaglandin d2 receptor antagonist
US20100260841A1 (en) *	2007-02-08	2010-10-14	Paolini John F	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched laropiprant
CN101559058B (zh) *	2008-04-16	2011-07-20	北京本草天源药物研究院	一种治疗血脂异常的药物组合物
RU2010151944A (ru) *	2008-05-20	2012-06-27	Серенис Терапьютикс С.А. (Fr)	Ниацин и нспвс для комбинированной терапии
WO2010030360A1 (en)	2008-09-11	2010-03-18	Arena Pharmaceuticals, Inc.	3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
EP2341773A4 (en) *	2008-09-24	2012-03-07	Merck Sharp & Dohme	PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
CN109044985A (zh)	2009-01-09	2018-12-21	前进制药知识产权有限公司	包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
EP2547672A1 (en)	2010-03-16	2013-01-23	Aventis Pharmaceuticals Inc.	Substituted pyrimidines as prostaglandin d2 receptor antagonists
TW201204708A (en)	2010-03-16	2012-02-01	Aventis Pharma Inc	A substituted pyrimidine as a prostaglandin D2 receptor antagonist
EP3256121B1 (en)	2015-02-13	2024-08-07	INSERM - Institut National de la Santé et de la Recherche Médicale	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr) *	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en) *	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) *	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
DE2857653A1 (de)	1977-09-30	1981-02-05	Rca Corp	Einrichtung in einem fernsehsystem
US4342767A (en)	1980-01-23	1982-08-03	Merck & Co., Inc.	Hypocholesteremic fermentation products
US4444784A (en)	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DK149080C (da)	1980-06-06	1986-07-28	Sankyo Co	Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US5021447A (en) *	1986-01-23	1991-06-04	Merck Frosst Canada, Inc.	Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4808608A (en) *	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) *	1986-03-27	1990-07-10	Merck Frosst Canada, Inc.	Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) *	1987-07-21	1988-10-04	Merck & Co., Inc.	Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
US5190972A (en) *	1992-01-27	1993-03-02	The University Of Melbourne	Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996032942A1 (en) *	1995-04-19	1996-10-24	Lipoprotein Technologies, Inc.	Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
CZ293957B6 (cs)	1995-10-31	2004-08-18	Scheringácorporation	@@Azetidinony substituované cukernými zbytkyŹ použitelné jako hypocholesterolemikaŹ farmaceutický prostředek a kit je obsahující
WO1997016424A1 (en)	1995-11-02	1997-05-09	Schering Corporation	Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
CZ288545B6 (cs)	1995-12-22	2001-07-11	Kowa Company, Ltd.	Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
US5886171A (en)	1996-05-31	1999-03-23	Schering Corporation	3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en)	1996-05-31	1998-04-14	Schering Corporation	3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en)	1996-10-29	1998-05-26	Schering Corporation	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
ATE359785T1 (de) *	1997-07-31	2007-05-15	Kos Life Sciences Inc	Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
US6469035B1 (en) *	1997-07-31	2002-10-22	Eugenio A. Cefali	Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US20010006644A1 (en) *	1997-07-31	2001-07-05	David J. Bova	Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
CA2307068C (en) *	1997-10-27	2007-04-10	Dr. Reddy's Research Foundation	Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6133001A (en)	1998-02-23	2000-10-17	Schering Corporation	Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en)	1998-10-02	1999-07-06	Schering Corporation	Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
ES2244238T3 (es)	1998-12-07	2005-12-01	Schering Corporation	Proceso para la sintesis de azetidinonas.
DE69911058T2 (de)	1998-12-23	2004-06-03	G.D. Searle Llc, Chicago	Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
HK1042115A1 (zh)	1999-04-05	2002-08-02	Merck Sharp & Dohme Corp.	配製1-(4-氟苯)-3(r)-[3(s)-氟氧基-3-(4-氟苯)丙基)]-4(s)-(4-羥苯基)-2-azetidinone的立體定向微生物降低法
WO2000063703A1 (en)	1999-04-16	2000-10-26	Schering Corporation	Use of azetidinone compounds
IT1306141B1 (it) *	1999-05-17	2001-05-30	Giampiero Valletta	Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
WO2003022814A1 (en)	2001-09-07	2003-03-20	Ono Pharmaceutical Co., Ltd.	Indole derivatives
NZ521192A (en)	2000-03-09	2005-01-28	Ono Pharmaceutical Co	Indole derivatives, process for preparation of the same and use thereof
US20010047027A1 (en) *	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
JP2002008186A (ja) *	2000-06-23	2002-01-11	Mitsubishi Heavy Ind Ltd	車種識別装置
US6410583B1 (en) *	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) *	2000-09-13	2007-03-07	三洋電機株式会社	映像信号処理回路
WO2002084298A2 (en)	2001-04-11	2002-10-24	Glaxo Group Limited	Medicaments which are modulators of hm74 and/or hm74a activity
AU2002302248B2 (en) *	2001-05-23	2008-03-06	Merck Frosst Canada Ltd.	Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
MXPA04009095A (es) *	2002-03-19	2004-12-06	Ono Pharmaceutical Co	Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo.
JP2005532338A (ja) *	2002-06-03	2005-10-27	ノバルティスアクチエンゲゼルシャフト	高脂質血症および関連疾患の処置のための置換シアノピロリジンの使用およびそれらを含む組み合わせ製剤
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) *	2005-07-01	2008-08-06	タキゲン製造株式会社	ステー

2004
- 2004-05-05 AR ARP040101527A patent/AR041089A1/es unknown
- 2004-05-06 JO JO200454A patent/JO2564B1/en active
- 2004-05-06 PE PE2004000463A patent/PE20050552A1/es not_active Application Discontinuation
- 2004-05-10 MY MYPI20041729A patent/MY140639A/en unknown
- 2004-05-13 NZ NZ572515A patent/NZ572515A/en not_active IP Right Cessation
- 2004-05-13 KR KR1020077029888A patent/KR100960749B1/ko not_active Expired - Fee Related
- 2004-05-13 EP EP04785539A patent/EP1624871B1/en not_active Expired - Lifetime
- 2004-05-13 WO PCT/US2004/014980 patent/WO2004103370A1/en not_active Ceased
- 2004-05-13 SI SI200431221T patent/SI1624871T1/sl unknown
- 2004-05-13 PT PT09163448T patent/PT2116244E/pt unknown
- 2004-05-13 DE DE602004022036T patent/DE602004022036D1/de not_active Expired - Lifetime
- 2004-05-13 GE GEAP200410277A patent/GEP20105025B/en unknown
- 2004-05-13 AU AU2004240597A patent/AU2004240597B2/en not_active Ceased
- 2004-05-13 CN CN2008101690579A patent/CN101559227B/zh not_active Expired - Fee Related
- 2004-05-13 DK DK04785539T patent/DK1624871T3/da active
- 2004-05-13 ME MEP-601/08A patent/MEP60108A/xx unknown
- 2004-05-13 JP JP2006515355A patent/JP4637833B2/ja not_active Expired - Fee Related
- 2004-05-13 DK DK09163448.5T patent/DK2116244T3/da active
- 2004-05-13 GT GT200400098A patent/GT200400098A/es unknown
- 2004-05-13 EP EP10182413A patent/EP2286816A1/en not_active Withdrawn
- 2004-05-13 RS RS20120499A patent/RS20120499A1/sr unknown
- 2004-05-13 MX MXPA05012272A patent/MXPA05012272A/es active IP Right Grant
- 2004-05-13 SG SG200708456-9A patent/SG153667A1/en unknown
- 2004-05-13 RS RS20120498A patent/RS20120498A1/sr unknown
- 2004-05-13 GE GEAP20049114A patent/GEP20084569B/en unknown
- 2004-05-13 CN CN2012100149106A patent/CN102526735A/zh active Pending
- 2004-05-13 NZ NZ543399A patent/NZ543399A/en not_active IP Right Cessation
- 2004-05-13 BR BRPI0410273-8A patent/BRPI0410273A/pt not_active IP Right Cessation
- 2004-05-13 UA UAA200512018A patent/UA89615C2/ru unknown
- 2004-05-13 PL PL04785539T patent/PL1624871T3/pl unknown
- 2004-05-13 PL PL09163448T patent/PL2116244T3/pl unknown
- 2004-05-13 KR KR1020057021795A patent/KR100806008B1/ko not_active Expired - Lifetime
- 2004-05-13 ES ES04785539T patent/ES2328148T3/es not_active Expired - Lifetime
- 2004-05-13 RS YU20050777A patent/RS52731B/sr unknown
- 2004-05-13 HR HR20090424T patent/HRP20090424T1/xx unknown
- 2004-05-13 ES ES09163448T patent/ES2392743T3/es not_active Expired - Lifetime
- 2004-05-13 EP EP09163448A patent/EP2116244B1/en not_active Expired - Lifetime
- 2004-05-13 EA EA200702674A patent/EA011895B1/ru not_active IP Right Cessation
- 2004-05-13 US US10/844,773 patent/US20040229844A1/en not_active Abandoned
- 2004-05-13 EA EA200501817A patent/EA009744B1/ru not_active IP Right Cessation
- 2004-05-13 CA CA2525772A patent/CA2525772C/en not_active Expired - Fee Related
- 2004-05-13 SI SI200431951T patent/SI2116244T1/sl unknown
- 2004-05-13 CN CNB2004800128531A patent/CN100441184C/zh not_active Expired - Fee Related
- 2004-05-13 PT PT04785539T patent/PT1624871E/pt unknown
- 2004-05-14 TW TW096125297A patent/TWI341199B/zh not_active IP Right Cessation
- 2004-05-14 PA PA20048603201A patent/PA8603201A1/es unknown
- 2004-05-14 DO DO2004000907A patent/DOP2004000907A/es unknown
- 2004-05-14 CL CL200401056A patent/CL2004001056A1/es unknown
- 2004-05-14 HN HN2004000171A patent/HN2004000171A/es unknown
- 2004-05-14 TW TW093113730A patent/TWI334354B/zh not_active IP Right Cessation
2005
- 2005-10-13 ZA ZA200508288A patent/ZA200508288B/xx unknown
- 2005-10-13 IS IS8071A patent/IS2708B/is unknown
- 2005-10-19 CR CR8047A patent/CR8047A/es unknown
- 2005-11-09 MA MA28589A patent/MA27835A1/fr unknown
- 2005-11-10 CO CO05114676A patent/CO5630034A2/es active IP Right Grant
- 2005-11-11 EC EC2005006156A patent/ECSP056156A/es unknown
- 2005-11-14 IL IL171962A patent/IL171962A/en not_active IP Right Cessation
- 2005-11-14 TN TNP2005000290A patent/TNSN05290A1/en unknown
- 2005-12-14 NO NO20055957A patent/NO20055957L/no not_active Application Discontinuation
2008
- 2008-03-11 CR CR9808A patent/CR9808A/es not_active Application Discontinuation
2009
- 2009-05-21 US US12/470,049 patent/US20090233977A1/en not_active Abandoned
- 2009-10-13 CY CY20091101051T patent/CY1109476T1/el unknown
- 2009-11-30 US US12/627,787 patent/US20100076002A1/en not_active Abandoned
- 2009-12-02 JP JP2009274146A patent/JP2010077151A/ja active Pending
2011
- 2011-01-24 US US13/012,696 patent/US20110118292A1/en not_active Abandoned
- 2011-03-07 AU AU2011200986A patent/AU2011200986B2/en not_active Ceased
2012
- 2012-10-11 HR HRP20120818TT patent/HRP20120818T1/hr unknown
- 2012-11-05 CY CY20121101050T patent/CY1113342T1/el unknown

Also Published As

Publication number	Publication date
JP2010077151A (ja)	2010-04-08
SG153667A1 (en)	2009-07-29
PA8603201A1 (es)	2005-02-04
HK1092722A1 (zh)	2007-02-16
EP1624871A1 (en)	2006-02-15
AR041089A1 (es)	2005-05-04
SI2116244T1 (sl)	2012-12-31
ECSP056156A (es)	2006-04-19
PL1624871T3 (pl)	2009-12-31
EA200501817A1 (ru)	2006-06-30
RS20050777A (sr)	2008-04-04
EP2116244B1 (en)	2012-08-08
RS20120499A1 (sr)	2013-08-30
RS20120498A1 (sr)	2013-08-30
AU2011200986A1 (en)	2011-03-31
MA27835A1 (fr)	2006-04-03
IS8071A (is)	2005-10-13
CN101559227A (zh)	2009-10-21
US20100076002A1 (en)	2010-03-25
GT200400098A (es)	2005-03-03
ES2392743T3 (es)	2012-12-13
HN2004000171A (es)	2011-07-11
CR8047A (es)	2006-07-14
EP2116244A1 (en)	2009-11-11
KR100960749B1 (ko)	2010-06-01
PT2116244E (pt)	2012-11-02
US20040229844A1 (en)	2004-11-18
DK2116244T3 (da)	2012-11-26
TWI334354B (en)	2010-12-11
PT1624871E (pt)	2009-09-07
CN1787819A (zh)	2006-06-14
AU2004240597A1 (en)	2004-12-02
DE602004022036D1 (de)	2009-08-27
ES2328148T3 (es)	2009-11-10
HRP20090424T1 (en)	2009-09-30
GEP20105025B (en)	2010-06-25
CO5630034A2 (es)	2006-04-28
IL171962A (en)	2012-06-28
TW200503757A (en)	2005-02-01
JP2006526030A (ja)	2006-11-16
GEP20084569B (en)	2008-12-25
CN100441184C (zh)	2008-12-10
DOP2004000907A (es)	2004-11-30
NO20055957L (no)	2006-02-14
CR9808A (es)	2008-07-29
NZ572515A (en)	2010-07-30
RS52731B (sr)	2013-08-30
MXPA05012272A (es)	2006-05-19
IS2708B (is)	2011-01-15
TW200803844A (en)	2008-01-16
PE20050552A1 (es)	2005-08-06
KR20080003470A (ko)	2008-01-07
AU2004240597B2 (en)	2011-01-06
CN101559227B (zh)	2012-03-21
JP4637833B2 (ja)	2011-02-23
AU2011200986B2 (en)	2012-11-08
CY1109476T1 (el)	2014-08-13
EA011895B1 (ru)	2009-06-30
CA2525772C (en)	2011-03-15
WO2004103370A1 (en)	2004-12-02
KR20060012617A (ko)	2006-02-08
IL171962A0 (en)	2006-04-10
EP2286816A1 (en)	2011-02-23
HRP20120818T1 (hr)	2012-11-30
BRPI0410273A (pt)	2006-05-16
CA2525772A1 (en)	2004-12-02
TNSN05290A1 (en)	2007-07-10
UA89615C2 (ru)	2010-02-25
CY1113342T1 (el)	2016-06-22
JO2564B1 (en)	2010-11-03
TWI341199B (en)	2011-05-01
CN102526735A (zh)	2012-07-04
MEP60108A (en)	2011-05-10
ZA200508288B (en)	2008-08-27
SI1624871T1 (sl)	2009-12-31
US20110118292A1 (en)	2011-05-19
CL2004001056A1 (es)	2005-03-28
NZ543399A (en)	2009-02-28
MY140639A (en)	2010-01-15
PL2116244T3 (pl)	2013-01-31
EA009744B1 (ru)	2008-04-28
KR100806008B1 (ko)	2008-02-26
EA200702674A1 (ru)	2008-04-28
US20090233977A1 (en)	2009-09-17
EP1624871B1 (en)	2009-07-15

Publication	Publication Date	Title
DK1624871T3 (da)	2009-11-16	Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger
DK1667986T3 (da)	2013-05-06	Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1628530T3 (da)	2012-07-23	Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK3159357T3 (da)	2022-04-04	Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner
DK1891571T3 (da)	2013-10-28	Hæmning af spredning af uønskede koder og data
NO20052547D0 (no)	2005-05-26	System og fremgangsmate for foretrukken applikasjonsinstallasjon og -eksekvering.
DK1550535T3 (da)	2020-01-27	Fremgangsmåde og indretning til fremstilling af betonmasse
DK1644021T3 (da)	2012-10-29	Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1791791T3 (da)	2019-08-26	Fremgangsmåder og sammensætninger til behandling af vand
DK1499184T3 (da)	2013-01-02	Sammensætninger til behandling af ektoparasitangreb
DK1440908T3 (da)	2007-01-08	Indsats og fremgangsmåde til fremstilling af drikkevarer
DK1539115T3 (da)	2008-01-28	Fremgangsmåder og doseringsformer til kontrolleret levering af paliperidon
DK1677735T3 (da)	2014-10-27	Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
DK1997512T3 (da)	2014-01-27	Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK1673214T3 (da)	2013-07-15	Apparat og fremgangsmåde til behandling af slam
DK1596868T3 (da)	2008-12-08	Fremgangsmåde til behandling af hjertesvigt og medikament dertil
DK1874557T3 (da)	2014-06-10	Identitetsdokument og fremgangsmåde til fremstilling deraf
DK1862158T3 (da)	2012-12-17	Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
DK1539200T3 (da)	2014-06-30	Fremgangsmåde til behandling af multipel sklerose
DK1883293T3 (da)	2010-09-20	Sammensætning og fremgangsmåde til kontrol af insekter
DK1478438T3 (da)	2012-08-27	Fremgangsmåder og sammensætninger til behandling af astma
DK1461047T3 (da)	2012-10-15	Sammensætninger og fremgangsmåde til behandling af dyr
DK1768489T3 (da)	2013-10-28	Apparat og fremgangsmåde til destruktion af vegetation
DK1599469T3 (da)	2006-10-09	Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
DK1589973T3 (da)	2010-07-19	Formulering og fremgangsmåder til behandling af thrombocytæmi